Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4673 - Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial

Date

10 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Urothelial Cancers

Presenters

Albert Font

Citation

Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371

Authors

A. Font1, F.X. Real2, J. Puente3, F.J. Vazquez Mazon4, N. Sala5, J.A. Virizuela6, A. Rodriguez-Vida7, E. Grande Pulido8, D. Castellano9, M.A. Climent10, E. Gallardo11, A. González del Alba12, P.L. Fernandez13, P. Jares13, I. Aldecoa13, N. Gibson14, J. Serra15, E.R. Imedio16, E. Ehrnrooth17, B. Mellado13

Author affiliations

  • 1 Institut Català D’ Oncologia, Hospital Universitari Germans Trias i Pujol (HUGTiP), 08916 - Barcelona/ES
  • 2 Universitat Pompeu Fabra, Barcelona, Es;, Centro Nacional de Investigaciones Oncológicas, Cancer Cell Biology Programme, Madrid/ES
  • 3 Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid/ES
  • 4 Medical Oncology, Hospital General Universitario de Elche, 3203 - Elche/ES
  • 5 Institut Català Oncologia (ico) Girona, Hospital Josep Trueta, Girona/ES
  • 6 Medical Oncology Dpto, Hospital Universitario Virgen Macarena, Seville/ES
  • 7 Medical Oncology, Hospital del Mar, 8003 - Barcelona/ES
  • 8 Medical Oncology, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 9 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 10 Medical Oncology, Instituto Valenciano de Oncología (IVO), Valencia/ES
  • 11 Oncology, Hospital Universitari Parc Taulí, Barcelona/ES
  • 12 Medical Oncology, Hospital Universitario Son Espases, Palma de Mallorca/ES
  • 13 Medical Oncology, Hospital Clínic de Barcelona, Barcelona/ES
  • 14 Translational Medicine And Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/DE
  • 15 Oncology, Boehringer Ingelheim España, S.A., Barcelona/ES
  • 16 Oncology, Boehringer Ingelheim Ltd, Bracknell/GB
  • 17 Ta Oncology, Boehringer Ingelheim, Danmark A/S, Copenhagen/DK
More

Resources

Abstract 4673

Background

First-line treatment of patients (pts) with advanced or metastatic UC consists of platinum-based chemotherapy (CT), and currently, there is no well-established therapy following CT failure. Recently, checkpoint inhibitors have shown clinical benefit in this setting, and are likely to become a future standard of care. However, to date, no other targeted therapies have shown significant clinical activity. Given that ∼20% of UCs harbour ERBB receptor alterations or abnormalities, the blockade of the ERBB pathway may be an effective therapeutic strategy. Indeed, afatinib, an irreversible ERBB family blocker, demonstrated activity in a Phase II trial in a subgroup of pts with UC harbouring ERBB2/ERBB3 aberrations. These data provide rationale for the current Phase II trial assessing afatinib in pts with UC, molecularly selected for ERBB receptor alterations (LUX-Bladder 1; NCT02780687).

Trial design

The Phase II, single-arm LUX-Bladder 1 trial evaluates the efficacy and safety of afatinib in pts with UC and ERBB2/ERBB3 mutations or ERBB2 amplification (Cohort A), or EGFR amplification (Cohort B). Eligible pts are ≥18 years of age, with histologically confirmed advanced/metastatic UC of the urinary tract not amenable to surgery and progression during or after platinum-based CT (previous immunotherapy allowed), ECOG PS 0–1, with archival tissue samples available for pre-screening biomarker analysis. Pts will receive oral afatinib 40 mg/day until disease progression or discontinuation for other reasons. Cohort A will enrol in two stages, with Stage (S) 2 enrolment depending on afatinib anti-tumour activity in S1. The primary endpoint and key secondary endpoint in Cohort A are PFS rate at 6 months and ORR; other secondary endpoints include PFS, OS, disease control rate, duration of response and tumour shrinkage. These endpoints will also be explored in Cohort B. Safety and biomarkers will be assessed in both cohorts. The trial commenced in June 2016. Recruitment is ongoing in Spain and planned in two additional European countries; planned enrolment: Cohort A, ∼70 pts (S1, n=∼25; S2, n=∼45); Cohort B, ∼10 pts.

Clinical trial identification

NCT02780687; 1200.261

Legal entity responsible for the study

Boehringer Ingelheim

Funding

Boehringer Ingelheim

Disclosure

J. Puente: Consulting/advisory role: Pfizer, Roche, Janssen, Lilly Speakers bureau: Pfizer, BI, Astellas Research funding: Astellas, Pfizer. F.J. Vazquez Mazon: Honoraria: Janssen/Astellas/Sanofi/Bayer/Novartis Consulting/ad board/Expert testimony: Janssen Astellas/Sanofi/Bayer/Novartis; Speaker: Novartis; Travel, accommodations, expenses: Astellas/Pfizer/Janssen. N. Sala: Consulting/advisory role: Astellas, Janssen, Pfizer, Bristol-Myers Squib; Speakers bureau: Astellas, Janssen, Pfizer, Bristol-Myers Squib; Travel, accommodations, expenses: Astellas, Pfizer, Janssen. E. Grande Pulido: Research funding: Astellas, Pfizer, AstraZeneca. D. Castellano: Honoraria: Pfizer, Astellas, Janssen; Consulting/advisory role: Roche, Epsen; Speakers bureau: Amgen, Novartis, Bristol-Myers Squib. M.A. Climent: Honoraria: Roche, Bristol-Myers Squib, Bayer, Astellas, Sanofi, Janssen, Pfizer, Novartis; Consulting/advisory role: Janssen, Pfizer, Roche, Sanofi, Astellas, Bayer; Travel, accommodation, expenses: Astellas, Janssen, Pfizer. P. Jares: Patents, royalities, other intellectual property: Barcelona University. I. Aldecoa: Travel, accommodation, expenses: Sysplex Espana S.L. N. Gibson, J. Serra, E.R. Imedio, E. Ehrnrooth: Employment: BI. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.